TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30501870

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (10 mg)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m²) with lenalidomide and dexamethasone (VRd) plus panobinostat (15 mg)
Number of subjects: 55
Study: 30501916

Group type: EXPERIMENTAL
Intervention: Calcium intake in normal weight children (859.0 ± 195.9 mg)
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 221
Study: 30503187

Group type: EXPERIMENTAL
Intervention: Increase in BUN ≥20% during hospitalization for AHF
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Worsening renal function (WRF)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Effective decongestion
Number of subjects: 247
Study: 30503846

Group type: EXPERIMENTAL
Intervention: Nonbland blue (NBB) post-EMR defect features including size, number, and herniation of submucosal vessels.
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Submucosal vessels in the left-sided colon segment.
Number of subjects: 501

Group type: COMPARATOR
Intervention: Presence of visible vessels, their diameter, herniation, or other nonvascular PED features.
Number of subjects: 501
Study: 30503909

Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation (CA) assessment at T1, T2, and T3; ARI values recorded: T1 (5.6 ± 1.7), T2 (3.9 ± 1.7), T3 (5.5 ± 1.8)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Dynamic cerebral autoregulation (CA) assessment
Number of subjects: 67
Study: 30503967

Group type: EXPERIMENTAL
Intervention: Low literacy level instructions and reminder calls
Number of subjects: 4916

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4916

Group type: EXPERIMENTAL
Intervention: Properly processed samples
Number of subjects: 4916

Group type: EXPERIMENTAL
Intervention: Improperly processed samples
Number of subjects: 4916
Study: 30505290

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 0
Study: 30505484

Group type: EXPERIMENTAL
Intervention: Modified ARDS prediction score (MAPS)
Number of subjects: 677

Group type: COMPARATOR
Intervention: Lung injury prediction score (LIPS)
Number of subjects: 677
Study: 30505830

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no probiotic supplementation)
Number of subjects: 0
Study: 30506110

Group type: EXPERIMENTAL
Intervention: Intravenous trastuzumab (H IV) treatment
Number of subjects: 3733
Study: 30506283

Group type: EXPERIMENTAL
Intervention: Personalized PRRT (adjusted injected activity to deliver a prescribed absorbed dose to the kidney)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Personalized PRRT
Number of subjects: 52
Study: 30506309

Group type: EXPERIMENTAL
Intervention: Daily home spirometry and accelerometry during the peri-diagnostic period
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Daily home spirometry and accelerometry
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes (PROs) assessed prior to or during site visits
Number of subjects: 180
Study: 30506341

Group type: EXPERIMENTAL
Intervention: Patients with PDN
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study: 30506361

Group type: EXPERIMENTAL
Intervention: Test product (aqueous dispersion of a novel silylated polyol)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Reference product (pyrethrum-based pediculicide)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Reference product (dimethicone)
Number of subjects: 70
Study: 30506533

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (2 cycles of CapeOX or 3 cycles of mFOLFOX6) followed by elective surgery
Number of subjects: 62

Group type: COMPARATOR
Intervention: Elective surgery without neoadjuvant chemotherapy
Number of subjects: 62
Study: 30507862

Group type: EXPERIMENTAL
Intervention: Automated office blood pressure (AOBP) measurement
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Quintiles of AOBP distributions
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Masked hypertension phenomena
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: White-coat hypertension phenomena
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Lower systolic AOBP
Number of subjects: 1208
Study: 30508064

Group type: EXPERIMENTAL
Intervention: Vaccinated both current and prior season
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccinated current season only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not vaccinated current and prior season
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vaccinated prior season only
Number of subjects: 0
Study: 30508076

Group type: EXPERIMENTAL
Intervention: RLD group (lead placement at the site of longest right-to-left electrical delay)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: RLD group
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: QRS width during RV pacing
Number of subjects: 211
Study: 30508189

Group type: EXPERIMENTAL
Intervention: MTX monotherapy
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: bDMARD monotherapy
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: bDMARDs + MTX
Number of subjects: 2778

Group type: EXPERIMENTAL
Intervention: bDMARDs + other csDMARDs
Number of subjects: 2778

Group type: COMPARATOR
Intervention: bDMARDs (all groups)
Number of subjects: 2778

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 2778

Group type: COMPARATOR
Intervention: MTX monotherapy and bDMARDs
Number of subjects: 2778
Study: 30508548

Group type: EXPERIMENTAL
Intervention: Pigmented Facial Lesion Scale
Number of subjects: 0
Study: 30508620

Group type: EXPERIMENTAL
Intervention: Inverse-planned, multibeam intensity modulated radiation therapy (IMRT)
Number of subjects: 113
Study: 30509206

Group type: EXPERIMENTAL
Intervention: Ear thermometer (Braun Thermoscan Pro 4000®)
Number of subjects: 599
Study: 30509218

Group type: EXPERIMENTAL
Intervention: Mindfulness Based Childbirth and Parenting (MBCP) Program
Number of subjects: 16
Study: 30509262

Group type: EXPERIMENTAL
Intervention: Nutrition care improvements implemented in five hospital units over one year (2016).
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Strategies to sustain changes in nutrition care practices.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Strategies to spread nutrition care improvements.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Strategies that supported both sustaining and spreading improvements.
Number of subjects: 126
Study: 30509296

Group type: EXPERIMENTAL
Intervention: Heparin treatment
Number of subjects: 9867

Group type: COMPARATOR
Intervention: Successful cfDNA assay without heparin
Number of subjects: 9867

Group type: EXPERIMENTAL
Intervention: Presence of autoimmune disease
Number of subjects: 9867

Group type: EXPERIMENTAL
Intervention: First-trimester combined screening
Number of subjects: 9867

Group type: EXPERIMENTAL
Intervention: Maternal weight
Number of subjects: 9867

Group type: EXPERIMENTAL
Intervention: Heparin (in vitro experiments)
Number of subjects: 9867
Study: 30509869

Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Number of subjects: 10
Study: 30510081

Group type: EXPERIMENTAL
Intervention: Intervention not specified
Number of subjects: 0
Study: 30510361

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 429

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 429
Study: 30510439

Group type: EXPERIMENTAL
Intervention: CKD patients
Number of subjects: 126

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 126
Study: 30510505

Group type: EXPERIMENTAL
Intervention: Pregabalin, dosage and duration not specified
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, treatment not specified
Number of subjects: 0
Study: 30510509

Group type: EXPERIMENTAL
Intervention: HR7056
Number of subjects: 63
Study: 30511200

Group type: EXPERIMENTAL
Intervention: TAS-114 combined with S-1, administered orally under fasting conditions at doses ranging from 5-240 mg/m
Number of subjects: 0
Study: 30511337

Group type: EXPERIMENTAL
Intervention: Estrogen/androgen effects on sex-related differences in myocardial ischemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Coronary angiographic reperfusion indexes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Platelet biology differences between men and women with IHD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Response to percutaneous coronary intervention, platelets, sex hormones, and myocardial damage at baseline
Number of subjects: 0
Study: 30511990

Group type: EXPERIMENTAL
Intervention: Fat grafting enriched with stromal vascular fraction
Number of subjects: 5
Study: 30512189

Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily until disease progression or study discontinuation
Number of subjects: 411
Study: 30513489

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT) for HD participants, 16 weekly sessions.
Number of subjects: 81

Group type: COMPARATOR
Intervention: Nonclinical control group, 16-week waiting period.
Number of subjects: 81
Study: 30514267

Group type: EXPERIMENTAL
Intervention: EHR-driven registry to facilitate patient transitions between primary and oncology care
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Co-locating a nurse practitioner trained in care coordination within a complex care team
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Enhancing teamwork through coaching
Number of subjects: 500
Study: 30514287

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 3000
Study: 30514326

Group type: EXPERIMENTAL
Intervention: Lognormal distribution analysis of postpartum blood loss
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lognormal distribution analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Three-parameter lognormal distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lognormal distribution approach
Number of subjects: 0
Study: 30514390

Group type: EXPERIMENTAL
Intervention: Durvalumab plus olaparib
Number of subjects: 17
Study: 30515367

Group type: EXPERIMENTAL
Intervention: Everolimus plus exemestane
Number of subjects: 241
Study: 30515430

Group type: EXPERIMENTAL
Intervention: Chronic HIV
Number of subjects: 149

Group type: COMPARATOR
Intervention: Elite Controllers
Number of subjects: 149

Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 149
Study: 30515599

Group type: EXPERIMENTAL
Intervention: Bayesian IRT Model
Number of subjects: 940
Study: 30515765

Group type: COMPARATOR
Intervention: Cannabidiol
Number of subjects: 23
Study: 30516520

Group type: EXPERIMENTAL
Intervention: AmpliPrep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MagNA Pure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QIAcube QBK
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QIAcube VRK
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual method (Instant Virus RNA/DNA kit)
Number of subjects: 0
Study: 30517603

Group type: EXPERIMENTAL
Intervention: Palivizumab
Number of subjects: 21107
Study: 30517722

Group type: EXPERIMENTAL
Intervention: Overnight spot samples with the Tanaka equation
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Overnight spot samples with the Brown equation
Number of subjects: 86

Group type: COMPARATOR
Intervention: Other equations (not specified)
Number of subjects: 86
Study: 30517727

Group type: EXPERIMENTAL
Intervention: Hazelnuts (∼57 g/d) for 16 weeks
Number of subjects: 32
Study: 30517728

Group type: EXPERIMENTAL
Intervention: Normozygous sickle cell children (HbAA)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Sickle cell trait (HbAS)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Normozygous (αα/αα) for α+-thalassemia
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Heterozygous (-α/αα) for α+-thalassemia
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: Homozygous (-α/-α) for α+-thalassemia
Number of subjects: 435
Study: 30518443

Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment group (110 patients)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Non-thrombolysis treatment group (94 patients)
Number of subjects: 204
Study: 30518449

Group type: EXPERIMENTAL
Intervention: Self-reported late sleep midpoint
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Self-reported short sleep duration
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Self-reported sleep midpoint
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Concordance between sleep diary and actigraphy for short sleep duration
Number of subjects: 10038

Group type: EXPERIMENTAL
Intervention: Concordance between sleep diary and actigraphy for sleep midpoint
Number of subjects: 10038
Study: 30518502

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (target dose of 2 × 10^5 cells) administered on day 0
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel
Number of subjects: 108
Study: 30518517

Group type: EXPERIMENTAL
Intervention: Structured communication intervention for family centered rounds; includes structured, high reliability communication, written real-time summaries, formal training for healthcare providers, and strategies for teamwork.
Number of subjects: 3106
Study: 30518543

Group type: EXPERIMENTAL
Intervention: Automated Aries molecular testing method
Number of subjects: 0
Study: 30519456

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30519467

Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU) under MR guidance
Number of subjects: 17
Study: 30519481

Group type: EXPERIMENTAL
Intervention: GO-OUT program (1-day workshop and 9-week outdoor walking group)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Workshop alone
Number of subjects: 9
Study: 30519877

Group type: EXPERIMENTAL
Intervention: Life support-based comprehensive treatment regimen including mechanical life support, immunological modulation with glucocorticoids and immunoglobulin, and antiviral reagents (neuraminidase inhibitor)
Number of subjects: 0
Study: 30520001

Group type: EXPERIMENTAL
Intervention: Bupropion XL 150 mg once daily for 5 days, then 300 mg once daily from days 6 to 14
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Bupropion XL
Number of subjects: 16
Study: 30520349

Group type: EXPERIMENTAL
Intervention: ICD shocks during sports participation
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Ventricular tachycardia/ventricular fibrillation storm
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Lead malfunction rates
Number of subjects: 129
Study: 30520689

Group type: EXPERIMENTAL
Intervention: Functional macrophage migration inhibitory factor (MIF) promoter polymorphism
Number of subjects: 0
Study: 30521125

Group type: EXPERIMENTAL
Intervention: Haematuria cancer risk score (HCRS)
Number of subjects: 4195

Group type: COMPARATOR
Intervention: UK National Institute for Health and Clinical Excellence guidelines
Number of subjects: 4195

Group type: COMPARATOR
Intervention: American Urological Association guidelines
Number of subjects: 4195
Study: 30521533

Group type: EXPERIMENTAL
Intervention: Pregabalin treatment
Number of subjects: 3962
Study: 30521759

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30522091

Group type: EXPERIMENTAL
Intervention: Parent-reported behavior problems on the Child Behavior Checklist (CBCL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internalizing, affective, and pervasive development problem behavior scores on the CBCL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Externalizing and anxiety problems on the CBCL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CBCL scores for boys and girls
Number of subjects: 0
Study: 30522571

Group type: EXPERIMENTAL
Intervention: Transtheoretical Model intervention
Number of subjects: 0
Study: 30522646

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with drug-eluting stents
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1900
Study: 30522700

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (10 mg/kg every 2 weeks for ≤24 months)
Number of subjects: 26
Study: 30522968

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30522992

Group type: EXPERIMENTAL
Intervention: Usual psychopharmacological therapy plus the Social-Local-Mobile app
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual psychopharmacological therapy
Number of subjects: 240
Study: 30523027

Group type: EXPERIMENTAL
Intervention: Ischemia identified by metrics of retinal vessel density
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Neurodegeneration identified by thinning of the retinal nerve fiber layer and/or ganglion cell layer
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Edema identified by thickening of the inner nuclear layer, outer plexiform layer, or full retina
Number of subjects: 142
Study: 30523039

Group type: EXPERIMENTAL
Intervention: Various modifiable risk factors (e.g., diet, supplement use, physical activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biomarkers (e.g., metabolomic, transcriptomic, metagenomic, genetic, epigenetic, proteomic markers)
Number of subjects: 0
Study: 30523489

Group type: EXPERIMENTAL
Intervention: Facilitated recall to clinicians
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Blood drug concentrations in plasma
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Self-report in online surveys
Number of subjects: 327
Study: 30523735

Group type: EXPERIMENTAL
Intervention: Thrombolysis extended to 9 hours from stroke onset
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30523748

Group type: EXPERIMENTAL
Intervention: UCB expanded ex vivo with nicotinamide
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard UCB transplantation (comparator)
Number of subjects: 36
Study: 30523943

Group type: EXPERIMENTAL
Intervention: Couch motion (dynamic tracking)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Couch static (control)
Number of subjects: 100
Study: 30524317

Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antidepressants
Number of subjects: 0
Study: 30524509

Group type: EXPERIMENTAL
Intervention: Triple therapy (varenicline + nicotine patch + nicotine lozenge)
Number of subjects: 36
Study: 30524702

Group type: EXPERIMENTAL
Intervention: Anti-TNF-alpha biologic infliximab
Number of subjects: 0
Study: 30524719

Group type: EXPERIMENTAL
Intervention: Preoperative isometric exercise (PIE) for 8 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study: 30524746

Group type: COMPARATOR
Intervention: Recommended gestational weight gain
Number of subjects: 80
Study: 30525116

Group type: EXPERIMENTAL
Intervention: LEV 1,000-3,000 mg/day
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study: 30525443

Group type: EXPERIMENTAL
Intervention: Custom-designed irinotecan silicasome (Ir-silicasome)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Onivyde
Number of subjects: 0

Group type: COMPARATOR
Intervention: Free drug (irinotecan)
Number of subjects: 0
Study: 30525951

Group type: EXPERIMENTAL
Intervention: Bifidobacterium infantis M-63 (1×10^9 CFU)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study: 30526163

Group type: EXPERIMENTAL
Intervention: Intramedullary nails with cannulated screws
Number of subjects: 96

Group type: COMPARATOR
Intervention: Inverted triangular cannulated compression screws
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 96
Study: 30526213

Group type: EXPERIMENTAL
Intervention: Cytisine, a partial agonist for the α4β2 nicotinic acetylcholine receptor, administered in ascending single doses.
Number of subjects: 0
Study: 30526232

Group type: EXPERIMENTAL
Intervention: 8-session gait retraining program with real-time biofeedback of braking forces
Number of subjects: 12
Study: 30526313

Group type: EXPERIMENTAL
Intervention: Blood donation within the past 12 months
Number of subjects: 2261

Group type: COMPARATOR
Intervention: No condomless anal intercourse (CAI)
Number of subjects: 2261

Group type: COMPARATOR
Intervention: Belief of no undiagnosed HIV infection
Number of subjects: 2261

Group type: COMPARATOR
Intervention: Past-12-month HIV testing
Number of subjects: 2261
Study: 30526535

Group type: EXPERIMENTAL
Intervention: Initial high-dose ganciclovir (6 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Maintenance dose of ganciclovir (not specified)
Number of subjects: 24
Study: 30526599

Group type: EXPERIMENTAL
Intervention: NK cells in BAL fluid
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: iNKT and NKT-like cells in BAL fluid
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: NK cells in BAL fluid of subjects that quit smoking
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Rate of lung function decline
Number of subjects: 52
Study: 30526611

Group type: EXPERIMENTAL
Intervention: Heart failure patients (n=27)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Healthy subjects (control group, n=14)
Number of subjects: 41
Study: 30526617

Group type: EXPERIMENTAL
Intervention: Stochastic Resonance (SR) Stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: No stimulation
Number of subjects: 20
Study: 30527084

Group type: EXPERIMENTAL
Intervention: RayPilot
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Calypso
Number of subjects: 48

Group type: COMPARATOR
Intervention: Fiducial markers (FM) and transponders
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: RayPilot transmitters
Number of subjects: 48
Study: 30527151

Group type: EXPERIMENTAL
Intervention: Cardiac complications (including atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, complete heart block, heart failure, stroke, endocarditis, myocardial infarction, pulmonary hypertension)
Number of subjects: 2731

Group type: EXPERIMENTAL
Intervention: Perioperative stroke
Number of subjects: 2731

Group type: EXPERIMENTAL
Intervention: Complete heart block
Number of subjects: 2731

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 2731

Group type: EXPERIMENTAL
Intervention: Atrial flutter
Number of subjects: 2731

Group type: EXPERIMENTAL
Intervention: All complications between ages 5 and 17 years
Number of subjects: 2731
Study: 30527203

Group type: EXPERIMENTAL
Intervention: Endocan levels in patients with VAP
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Endocan levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum Endocan level on day 3
Number of subjects: 60

Group type: COMPARATOR
Intervention: PCT, WBC, CRP measurements
Number of subjects: 60